Authors
Loading...
Research demonstrates improved ICB response in melanoma and colorectal cancer due to TET2 inactivation, suggesting a biomarker for therapy.
Rondeau et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: